PRODUCTS & SERVICES
Custom Oligonucleotides Services
We are proud to announce that MultiplexDX has won Biotechnology Standard of Excellence and Technology Standard of Excellence in the 2018 WebAwards organized by the Web Marketing Association (WMA). Independent expert judges from around the world gave MultiplexDX official website the highest scores for the innovation, design, content, ease of use, interactivity, copywriting and technology.
Dr. Pavol Cekan, Founder and CEO of MultiplexDX, comments:
We are innovative in everything! Be it our products, marketing strategy or web presence. We are lucky to have a team of really forward-thinking people who generate new approaches and find efficient ways how to hit the market. All our recent awards prove that we chose a right direction and underline the quality of the work we are doing.
MultiplexDX website was developed by Vesturbaer, which is also a co-winner of the WMA WebAwards 2018. Vesturbaer is a marketing consulting company and a reliable partner of MultiplexDX from the very start. The awards details can be found on the official WMA website
Since 1997, the Web Marketing Association's annual WebAward Competition has been setting the standard of excellence for Website development. Independent expert judges from around the world review sites in 96 industries. The best are recognized with a WebAward which helps interactive professionals promote themselves, their companies, and their best work to the outside world. The WebAward Competition is the premier award recognition program for Web developers and advertising agencies.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.